It has been shown that patients without EGFR‐TKIs benefit more from immunotherapy compared with TKI experienced, since EGFR‐TKIs foster the TME associated with tumor immune escape via the innate immune signaling pathway of type I IFNs[431] or upregulate innate immune checkpoint CD24.[432]. Here, CD24 is linked to neoplasm.